Skip to main content
. 2017 Aug 8;76(11):1924–1930. doi: 10.1136/annrheumdis-2017-211351

Figure 2.

Figure 2

Receiver operating characteristic curves for (A) the number of dominant clones, (B) the impact of all dominant clones combined and (C) the impact of the most dominant clone in at-risk individuals (n=21). The development of arthritis was analysed after 36 months of follow-up. The arrow points to the cut-off value chosen, and the corresponding value is shown. (D) Kaplan-Meier curve for BCR-clone positive and BCR-clone negative individuals in the test cohort, assuming the at-risk individuals analysed represent a random selection of the total at-risk individuals (n=65). (E) Kaplan-Meier curve for BCR-clone positive and BCR-clone negative individuals in the validation cohort. (F) Table describing sensitivity, specificity, PPV and NPV including 95% CIs for the BCR-clone model, in the test cohort and the validation cohort. AUC, area under the curve; BCR, B-cell receptor; NPV, negative predictive value; PPV, positive predictive value.